A Genome-wide RNAi Screen for Modifiers of the Circadian Clock in Human Cells  by Zhang, Eric E. et al.
Resource
A Genome-wide RNAi Screen
for Modifiers of the Circadian Clock
in Human Cells
Eric E. Zhang,1,2,5 Andrew C. Liu,1,3,5 Tsuyoshi Hirota,1,2,5 Loren J. Miraglia,1 Genevieve Welch,1
Pagkapol Y. Pongsawakul,2 Xianzhong Liu,1 Ann Atwood,2 Jon W. Huss III,1 Jeff Janes,1 Andrew I. Su,1
John B. Hogenesch,4,* and Steve A. Kay2,*
1Genomics Institute of the Novartis Research Foundation, San Diego, CA 92121, USA
2Section of Cell and Developmental Biology, Division of Biological Sciences, University of California, San Diego, La Jolla,
CA 92093-0130, USA
3Department of Biology, The University of Memphis, Memphis, TN 38152, USA
4Department of Pharmacology, Institute for Translational Medicine and Therapeutics, Penn Genome Frontiers Institute,
University of Pennsylvania School of Medicine, Philadelphia, PA 19104-6160, USA
5These authors contributed equally to this work
*Correspondence: hogenesc@mail.med.upenn.edu (J.B.H.), skay@ucsd.edu (S.A.K.)
DOI 10.1016/j.cell.2009.08.031SUMMARY
Two decades of research identified more than a
dozen clock genes and defined a biochemical feed-
back mechanism of circadian oscillator function. To
identify additional clock genes and modifiers, we
conducted a genome-wide small interfering RNA
screen in a human cellular clock model. Knockdown
of nearly 1000 genes reduced rhythm amplitude.
Potent effects on period length or increased ampli-
tude were less frequent; we found hundreds of these
and confirmed them in secondary screens. Charac-
terization of a subset of these genes demonstrated
a dosage-dependent effect on oscillator function.
Protein interaction network analysis showed that
dozens of gene products directly or indirectly asso-
ciate with known clock components. Pathway anal-
ysis revealed these genes are overrepresented for
components of insulin and hedgehog signaling, the
cell cycle, and the folate metabolism. Coupled with
data showing many of these pathways are clock
regulated, we conclude the clock is interconnected
with many aspects of cellular function.
INTRODUCTION
Circadian rhythms in mammals are exemplified by the sleep/
wake cycle and regulated by an internal timing system. A central
clock in the suprachiasmatic nuclei (SCN) of the hypothalamus
coordinates input and, through a complex signaling cascade,
synchronizes local clocks in the brain and throughout the body
(Reppert and Weaver, 2002; Panda et al., 2002b; Liu et al.,
2007a). Over the past two decades, extensive genetic, genomic,
molecular, and cell biological approaches identified more thana dozen clock genes that collectively comprise a biochemical
feedback loop that drives circadian oscillations (Reppert and
Weaver, 2002; Panda et al., 2002b).
Recent models consider the clock a biochemical and cellular
oscillator, and also a genetic network. A highly conserved nega-
tive feedback loop was discovered and elucidated at biochem-
ical, cellular, and organismal levels in mammals and Drosophila;
transcription factors play a prominent role in the clock mecha-
nism. The bHLH-PAS transcriptional activators BMAL1 (official
name: ARNTL, an ortholog of the Drosophila cyc gene) and its
heterodimeric partner CLOCK (an ortholog of the Drosophila
Clk gene) interact to bind to E-box cis elements present in the
promoter regions of their target genes. These targets include
two families of repressor proteins, the PERIODs (PER1, PER2,
and PER3) and the CRYPTOCHROMEs (CRY1 andCRY2), which
interact in a protein complex that translocates from the cyto-
plasm to the nucleus. In the nucleus, this repressor complex
physically associates with the BMAL1-CLOCK complex to inhibit
E-box-mediated transcription. This process results in the cyclic
transcription of these repressor genes, as well as thousands of
transcriptional output genes elsewhere in the genome (Hughes
et al., 2009; Panda et al., 2002a; Ueda et al., 2002).
In addition to rhythmic transcription, PER and CRY protein
levels and subcellular localization also oscillate. Protein level
cycling is a consequence of the transcriptional regulation
mentioned above, but also through posttranscriptional and
posttranslational mechanisms that regulate the stability and
degradation of messages and proteins. These processes are
mediated by kinases (e.g., CSNK1D, CSNK1E, CSNK2, and
GSK3B) (Vanselow et al., 2006; Maier et al., 2009; Hirota et al.,
2008; Etchegaray et al., 2009) and the proteasomal machinery,
including the E3 ligase, FBXL3 (Siepka et al., 2007; Busino
et al., 2007; Godinho et al., 2007; Reddy et al., 2006). Thus, while
transcriptional regulation generates rhythmic RNA levels, regu-
lated posttranslational modifications control protein abundance,
subcellular localization, and repressor activity of PER and CRY.Cell 139, 199–210, October 2, 2009 ª2009 Elsevier Inc. 199
Importantly, these additional regulatory steps introduce a delay,
critical for rhythm generation and period regulation, in the clock
mechanism (Gallego and Virshup, 2007).
The circadian oscillator is also a highly interconnected genetic
network that uses other transcription factors and response
elements. In addition to the biochemical feedback loop that
regulates cycling at the E-box (termed the ‘‘core loop’’), circa-
dian gene expression is mediated by transcription at the ROR/
REV-ERB (RORE) and the DBP/E4BP4 (D-box) binding ele-
ments. Two subfamilies of nuclear hormone receptors, the
NR1Ds (NR1D1 and NR1D2, or REV-ERBa and b) and RORs
(a, b and g, or RORa, RORb andRORc), either repress or activate
gene transcription from the ROR elements in several clock genes
(Ukai-Tadenuma et al., 2008). The bZIP transcription factors,
DBP, TEF, and HLF, perform similar functions on the D-box
element (Gachon et al., 2006).
The role of these genes was examined in vivo and in vitro.
Knockout mice for Rev-erba, Rora, or Rorb, have lower ampli-
tude rhythms, abnormal period lengths, and interindividual vari-
ability in both phenotypes (Andre et al., 1998; Preitner et al.,
2002; Sato et al., 2004). A coactivator shown to interact with
the ROR proteins, PGC1a, modulates Bmal1 expression, and
Pgc1a knockout mice display long-period locomotor activity
behavior (Liu et al., 2007c). Furthermore, dose-dependent
knockdown of ROR and REV-ERB genes in vitro has a potent
effect on the baseline and the amplitude of circadian gene
expression (Baggs et al., 2009). Taken in sum, these data
demonstrate the important role of the clock gene network in
regulating circadian amplitude, resistance to perturbation, and,
in several cases, modulation of period length.
Although the clock can function in a cell-autonomous manner
(for discussion purposes, we extend the definition of autonomy
to include potential auto regulation in trans), in vivo rhythms in
physiology and behavior result from more complex cellular and
humoral interactions. Genetic dissection of the circadian system
showed the important role of intercellular coupling in generating
physiological and behavioral responses; these explain the
apparent discordance among observations from cells, organo-
typic SCN cultures, and whole animals (Liu et al., 2007b). For
example, although Cry1 deletion in mice causes short period
length of locomotor activity rhythms, dissociated SCN neurons
and peripheral cells derived from these mice are arrhythmic
(Liu et al., 2007b). These results demonstrate that intercellular
coupling in the SCN compensates for the loss of Cry1 function
and, as a result, masks the more severe cellular clock deficits.
Similarly, while Clock gene knockout mice are nearly wild-type
in their behavioral rhythms, lung and liver preparations from
these mice display arrhythmic gene expression (DeBruyne
et al., 2006, 2007). In fact, cellular clock defects are often more
severe than behavioral in clock gene knockout mice (Brown
et al., 2005; Liu et al., 2007b). Thus, although transcriptional
rhythms are cell autonomous and reflect the cellular nature of
the circadian signaling, physiology and behavior result from
more complex in vivo interactions.
The circadian research community took nearly four decades to
identify the above clock components. In metazoan models,
successful approaches included forward mutagenesis in flies
and mice and cellular and biochemical methods followed by200 Cell 139, 199–210, October 2, 2009 ª2009 Elsevier Inc.confirmatory reverse genetics. Although these efforts were fruit-
ful, they remain incomplete because evidence, including quanti-
tative trait loci (QTL) studies, suggests that additional clock
components and modulators exist (Takahashi, 2004).
Remarkably, circadian clocks exist in cell lines (Balsalobre
et al., 1998). Some of these lines are amenable to complemen-
tary DNA (cDNA) overexpression and RNA interference (RNAi)
techniques and have been used to identify new components of
many signal transduction pathways (for example, see Conkright
et al., 2003; Iourgenko et al., 2003; Aza-Blanc et al., 2003). To
conduct a whole-genome screen for circadian clock modifiers,
we used the U2OS (human osteosarcoma) cell line that was
successfully employed in chemical screens (Hirota et al.,
2008), in dissection of network properties of the oscillator (Baggs
et al., 2009), and in a limited-scale RNAi screen (Maier et al.,
2009). We screened 90,000 individual small interfering RNAs
(siRNAs) and measured luciferase reporter gene expression
every 2 hr for 4 days. We applied statistical algorithms to find
modifiers of rhythm amplitude and period length. Knockdown
of nearly 1000 genes reduced rhythm amplitude. On the other
hand, knockdown of hundreds of genes by multiple independent
siRNAs generated strong circadian phenotypes. Characteriza-
tion of a subset of these genes demonstrated a dosage-depen-
dent effect on clock function. Protein interaction network anal-
ysis indicated that some candidates directly or indirectly
interact with known clock components. Gene expression studies
showed that some affect the clock by regulating clock compo-
nent expression levels. Finally, to disseminate this data and inte-
grate with existing public resources, we constructed a database
(http://biogps.gnf.org/circadian/). This resource will serve the
research community in genetic and biochemical investigations
of circadian regulation of physiology and behavior.
RESULTS
Assay Development
Because circadian rhythms are dynamic, we employed kinetic,
rather than steady-state, bioluminescence detection to assess
the persistence and characteristics of rhythms after perturba-
tion. To conduct such a screen, we required a cell line amenable
to efficient reverse transfection, where siRNAs are deposited on
plates, dried, mixed with transfection reagents and, finally, cells
are added to complete the transfection process. We chose
U2OS cells for assay development as this model was extensively
characterized by functional studies examining knockdown
effects of all known clock components with cellular and behav-
ioral phenotypes in knockout mice (Baggs et al., 2009; Liu
et al., 2007b). In addition, this model was used in small molecule
screening and limited-scale RNAi screening to find modifiers of
amplitude and periodicity (Hirota et al., 2008; Maier et al.,
2009; Baggs et al., 2009).
We established cell lines harboring a rapidly degradable form
of luciferase, dLuc, driven by the mouse Bmal1 or Per2 gene
promoter (Liu et al., 2008) (Figure S1 available online). Knock-
down of CRY1, CRY2, and BMAL1 in both lines resulted in
phenotypes consistent with previous knockout mouse and
cellular knockdown studies (Liu et al., 2007b, 2008; Maier
et al., 2009; Baggs et al., 2009) (Figure S1). For instance, CRY1
knockdown shortens period length and compromises rhythm
persistence, CRY2 knockdown lengthens period length, and
knockdown of both results in arrhythmicity.
We next adapted these assays for high-throughput screening
(HTS) in 96- and 384-well plates. By optimizing growth condi-
tions and transfection efficiency, we obtained consistent biolu-
minescence rhythms in a HTS format (e.g., ± 0.5 hr of SD in
control wells of 384-well plates, n = 7680 wells) with knockdown
effects for period and amplitude (see below). Knockdown of
known clock components such as CRY1, CRY2, and BMAL1 in
this format produced similar cellular clock phenotypes to those
in LumiCycle assays using 35 mm dishes (Figure S1). These
conditions enabled large-scale siRNA screens.
Primary Screen
The screening protocol and logic are outlined in Figures 1A and
S2 and describe the primary screen, data mining, hit selection,
secondary screen, and validation studies. The Bmal1-dLuc line
was more robust than our Per2-dLuc line and therefore was
used for primary screens in a 384-well format. CRY2 siRNAs
were used as positive controls in each plate. We screened an
siRNA library (QIAGEN) targeting 17,631 known and 4837 pre-
dicted human genes. In these libraries, four siRNA constructs
were designed for each gene with a pool of two siRNAs per
well (two siRNAs/well, two wells/gene) for a total of 89,872
siRNAs. These siRNAs were prespotted on 384-well plates. After
addition of transfection reagent, we seeded approximately 2000
cells into each well to complete the transfection. We measured
bioluminescence every 2 hr for 4 days for a total of 48 time points
for each well; this temporal resolution was chosen based on
simulation studies using data collected from known clock gene
perturbation. The primary screen produced a total of >4.3 3
106 data points, which are also deposited in the PubChem
Bioassay database (accession number AID 1904; see the Exper-
imental Procedures for details).
Data Mining
We used the MultiCycle Analysis program (Actimetrics) to
analyze period length and rhythm amplitude for each well.
Plate-to-plate variation in period length and amplitude was
modest in control wells (period length or t = 25.20 hr ± 0.55
[mean ± SD], n = 1176; amplitude or A = 4380 ± 1010, n =
1176) (Figures 1B and S3). Knockdown of CRY2, a period length
control, resulted in robust lengthening (29.43 hr ± 0.65; n =
1176), while knockdown of BMAL1, an amplitude control,
potently reduced amplitude (692 ± 626 arbitrary luminescence
units; n = 1176).
Gratifyingly, many known clock components had phenotypes
in this screen consistent with those seen in knockout animals (Liu
et al., 2007b; Liu et al., 2008) or dose-dependent siRNA knock-
down (Baggs et al., 2009) (Figure 1C). For example,CRY2 knock-
down lengthened period, andCRY1 knockdown led to rapid loss
of rhythmicity. Knockdown of BMAL1 or CLOCK genes resulted
in low amplitude/arrhythmicity, and knockdown ofPER1 orPER2
also caused almost immediate arrhythmicity. Consistent with its
role as a repressor for RORE-mediated transcription, knock-
down of NR1D1 raised overall reporter expression levels and
lengthened the period (see below), consistent with a previousreport (Baggs et al., 2009). We also saw knockdown effects for
CSNK1D and CSNK1E (Xu et al., 2005; Meng et al., 2008; Gal-
lego and Virshup, 2007; Etchegaray et al., 2009), GSK3B
(Hirota et al., 2008), FBXL3 (Siepka et al., 2007; Busino et al.,
2007; Godinho et al., 2007), FBXW11 (or b-TRCP2), and
CSNK2 (Maier et al., 2009). Collectively, these results support
the suitability of our primary screen.
Primary Hit Selection
To identify genes whose knockdown modulates the circadian
clock, rather than the overall health of the cells, we focused on
period length deficits and increased amplitude of rhythmicity.
Low-amplitude traces usually exhibit poor curve fitting and
generate inconsistent period length data between replicate
wells; they constitute less than 4.5% of all wells and were
excluded from the analysis (Figure S4). We found 1028 short-
period hits, including 76 genes that were hit by two independent
siRNA pairs (double hits), 4230 long-period hits (274 double hits),
and 493 high-amplitude hits (18 double hits) (Figure 1B). Consis-
tent with data from small molecule screens (Hirota et al., 2008)
(T.H andS.A.K., unpublished data) and previousmodel organism
screens (Takahashi, 2004), many more genes generated long
period length than short.
As siRNAs have well described potential ‘‘off target’’ effects,
we focused on genes where two or more independent siRNAs
generated a consistent phenotype (Echeverri et al., 2006). The
plotted traces for these genes were individually inspected to
remove false positives caused by poor curve fitting. We selected
254 genes whose knockdown resulted in strong circadian phe-
notypes, defined by three or more standard deviations from
the mean, in period length and rhythm amplitude (Figure S2).
We also selected 89 single siRNA pair hits that showed strong
circadian phenotypes in duplicate wells (Figure S2). Thus, our
primary hit selection list contains a total of 343 genes including
known clock components (Table S1 and Figure 1).
Secondary Confirmation Screen
Next, we performed a secondary screen to confirm the knock-
down phenotypes identified in the primary screen (Figure S2).
We tested at least four siRNA constructs (one siRNA/well, at
least four wells/gene) for each gene in both the Bmal1-dLuc
and Per2-dLuc reporter cell lines (Figure S1). We hypothesized
that consistent changes in both assays indicate that resultant
phenotype is not reporter or response element specific, but
rather reports an impact on clock function in cells.
As expected, the secondary screen using a Bmal1-dLuc
reporter assay generated highly concordant results with the
primary screen (Figures 2A and S2): 222 of 238 genes that
were identified in the primary screen with two siRNA pairs and
47 of 83 with a single siRNA pair were confirmed (Table S1). In
Per2-dLuc reporter assay, 219 were also independently
confirmed (Figures 2B–2D and S2). The remaining unconfirmed
genes either failed to have more than one independent siRNA
conferring a consistent phenotype or confirmed in the Bmal1-
dLuc but not the Per2-dLuc assay. In addition, a few genes
altered both period length and amplitude in these assays
(Figure S2). In summary, we observed a high level of concor-
dance between our primary and secondary screens, and weCell 139, 199–210, October 2, 2009 ª2009 Elsevier Inc. 201
identified hundreds of genes whose knockdown generates
strong circadian phenotypes.
Dose-Dependent Phenotypic Validation
To determine those genes that most sensitively impacted period
length or increased amplitude (cellular rheostats of clock func-
tion), we conducted a dosage-dependent knockdown analysis
as per our previous work (Baggs et al., 2009). In this study, we
selected 17 genes from the primary screen with extreme pheno-
types and generated an eight-point dose response. All but one
showed dose-dependent effects on circadian rhythms (Fig-
ure 3A). Gene knockdown was confirmed by quantitative PCR
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Figure 1. A Cell-Based Genome-wide siRNA Screen for Circadian Clock Modifiers
(A) A schematic diagram of the genome-wide siRNA screen including the primary screen, data mining, hit selection, secondary screen, and validation of several
selected targets. In the primary screen, reporter cells were transfected with siRNA in 384-well plates followed by kinetic bioluminescence recording (see the
Experimental Procedures for details). Luminescence data were analyzed to obtain circadian parameters and select primary hits. Secondary screen and validation
studies were performed to confirm circadian phenotypes of hits and to demonstrate the validity of the primary screen. To catalyze the use of this dataset by the
research community, we constructed a comprehensive circadian genomic screen database in BioGPS (see Figure S6 for details).
(B) Distribution of circadian parameters of the entire primary screen. Dots represent normalized period (upper) and amplitude values (lower). For period length, the
average of duplicate wells was divided by the mean of the entire screen and indicated in Log2 space. The cutoff was 0.1 and +0.1 (corresponding to raw data
23.55 hr for short- and 26.85 hr for long-period hits). Traces that lack apparent24 hr bioluminescence oscillation usually returned as a period length of 48 hr and
are considered as arrhythmic. In addition, Log2 values above 0.4 (corresponding to 38 hr), for example, display poor curve fitting and are also considered as
arrhythmic. For rhythm amplitude, average of duplicate wells was divided by the mean of the entire screen, and the cutoff was 2.20 (corresponding to raw
data 7390) for high-amplitude hits. The knockdown phenotypes of several representative clock genes are shown in colored dots.
(C) Cellular clock phenotypes of siRNA knockdown of known clock genes. Plots of cellular oscillations upon knockdown of BMAL1,CLOCK, PER1, PER2,CRY1,
orCRY2 by two independent pairs of siRNAs in the primary screen are presented. The spikes of initial 10 hr bioluminescence readings resulted frommedia change
and were removed from the plot.202 Cell 139, 199–210, October 2, 2009 ª2009 Elsevier Inc.
(Q-PCR) (Figure 3B). Genes whose knockdown lengthened
period included HCFC1, POLR3F, PRPF4, SEC13, UNC119,
and ZMAT3, similar to CRY2 or FBXL3. Knockdown of ACSF3,
B4GALT2, CEACAM21, TBCB, or MPG led to dose-dependent
period shortening, similar to CRY1. Finally, knockdown of
COX4NB, FHIT, HIST1H1B, NMNAT1, or PDE1B caused dose-
dependent increases in rhythm amplitude. These data confirm
primary screening results and show that many genes from our
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Figure 2. Secondary Confirmation Assay of Cellular Clock Phenotypes
(A) A heat map of the secondary screen usingBmal1-dLuc cells. Eight hundred and seventy-two independent siRNAs were tested against 154 genes in duplicate,
along with 20 wells for each of the controls (GL2, CRY2, BMAL1, and GL3 siRNAs) for a total of 1824 wells. Bioluminescence intensity for each well was plotted
against time (hr), with each horizontal line representing luminescence recordings from a single well. The circadian profiles from each well were classified by hier-
archical clustering (clustering method: maximum complete linkage; similarity measure: correlation; ordering function: average value).
(B–D) Circadian parameters for 17 genes generating long-period (B), short-period (C), and high-amplitude phenotypes (D) in bothBmal1-dLuc and Per2-dLuc cell
lines. CRY2 siRNA was a positive control. For the Bmal1-dLuc cell line, the period length of the control wells was 25.07 hr ± 0.59 and amplitude was 4120 ± 1285
(mean ± SD; n = 768). For the Per2-dLuc cell line, the period length was 24.18 hr ± 0.55 and amplitude was 6438 ± 1140 (n = 768). Cellular clock phenotypes are
color coded, with darker colors in each category representing stronger alteration of circadian parameters (mean ± 3 3 SD) than lighter colors (mean ± 2 3 SD).
Four different siRNAs (y axis) were tested for each gene, and the assay was conducted in duplicates (x axis) in each screen using eitherBmal1-dLuc or Per2-dLuc
cells.Cell 139, 199–210, October 2, 2009 ª2009 Elsevier Inc. 203
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Figure 3. Dose-Dependent Phenotypic Validation
(A) Dose-dependent effects on circadian phenotypes.Bmal1-dLuc cells were transfectedwith the indicated amounts of siRNAs (eight-point, 2-fold dilution series;
8–1000 fmol/well) against 17 genes, and bioluminescence oscillations were recorded. Representative bioluminescence profiles (left) and circadian parameters
(right) are indicated. Data represent the mean ± SD (n = 3).
(B) Knockdown of target genes.Bmal1-dLuc cells were transfected with 3000 fmol/well siRNAs (corresponding to 1000 fmol/well on 384-well plate) and subjected
to Q-PCR analysis under unsynchronized conditions. mRNA levels of target genes relative to GAPDH are indicated. Data represent the mean ± SD (n = 2). In
parallel experiments, bioluminescence rhythms were recorded and circadian phenotypes were confirmed.screen impact clock function equivalently to or better than
known clock components.
Dose-Dependent Effects on Clock Gene Expression
Because of the complex regulatory architecture of the clock
gene network, perturbation of one clock component can lead
to dynamic changes in the levels of others (we describe these
as ‘‘network effects’’). To determine whether genes from our
screen had these effects, we selected a subset of genes that
were confirmed in dose response (Figure 3): POLR3F, PRPF4,
and SEC13 (long-period hits), ACSF3 and MPG (short-period
hits), and COX4NB (high-amplitude hit) to analyze their potential
for network effects. (The technical demands of this experiment
prevented us from extending this analysis to all genes from204 Cell 139, 199–210, October 2, 2009 ª2009 Elsevier Inc.Figure 3.) Knockdown of known clock genes had potent effects
on circadian phenotypes, as well as clock gene expression (Fig-
ure 4), consistent with a previous study (Baggs et al., 2009). Inter-
estingly, knockdown of most screen hits led to dose-dependent
reduction of NR1D1 and DBP transcript levels (Figure 4), consis-
tent with E-box-driven regulation (Ueda et al., 2005; Liu et al.,
2008; Baggs et al., 2009). These observations provide additional
support for the notion that regulation of E-box-mediated tran-
scription represents a topological vulnerability in mammalian
circadian clocks (Ueda et al., 2005).
Similar to NR1D1 knockdown, SEC13 knockdown upregu-
lated BMAL1 transcription; like NR1D1, SEC13 may impact
clock function through network effects, rather than direct phys-
ical association with clock components. Intriguingly, knockdown
of ACSF3 and POLR3F did not impact expression of core clock
genes despite dose-dependent functional consequences on the
clock (Figure 4). We note that CRY2 knockdown also does not
alter the messenger RNA (mRNA) levels of known clock genes.
These genes may regulate posttranslational modification of
clock components and impact protein abundance, localization,
or function to perturb the oscillator.
Protein Interaction Network Analysis
We hypothesized that some hits from our screen directly or indi-
rectly associate with known clock components. Using the Entrez
Gene and Prolexys protein-protein interaction databases (Pro-
lexys Pharmaceuticals, UT), we identified a comprehensive set
of proteins that interacted with gene products of screen hits or
known clock components (Table S2). To visualize the global
topography of these interactions, we constructed an expanded
clock gene interaction network (Figure 5). Most genes identified
in our screen are present in a highly connected cluster of proteins
centered on the core clock components: BMAL1, CLOCK, PERs,
and CRYs. While ZMAT3, BLNK, and RRP12 directly interact
with core clock components, most others associate indirectly
through bridging molecules. (Many of these bridging molecules
have phenotypic effects in our screen, but fell short of our report-
ing threshold.) For example, P53 (official name: TP53, tumor
protein 53) physically interacts with CDK9, MAPK8, NCL,
ABL1, BCR, DHFR, and BRCA2, as well as PCAF and CSNK1E;
knockdown of these genes generate short-period, long-period,
and high-amplitude phenotypes in our screen. Knockdown of
P53 itself generated low-amplitude rhythms in our screen;
U2OS cells are wild-type for P53 expression (Florenes et al.,
1994). Interestingly, a recent RNAi screen showed that BMAL1
potently regulates P53 pathway function (Mullenders et al.,
2009). Taken together, these observations provide evidence of
the interconnectedness between the circadian clock and many
other cellular pathways.
Pathway Analysis of Primary Screen Hits
Although the protein interaction network analysis gave some
sense of pathway regulation, we sought to directly test for func-
tional interconnectedness between the clock and other biolog-
ical processes using the NIH DAVID pathway analysis tool
(Huang et al., 2009; Dennis et al., 2003). We found that hits
from our screen were members of dozens of cellular pathways.
In addition, several pathways were overrepresented in this anal-
ysis, including insulin signaling (p < 0.013), hedgehog signaling
(p < 0.0088), cell cycle (p < 0.054), and folate metabolism
(p < 0.014) (Figures 6A and S5). While inhibition of multiple
components of the insulin, hedgehog, or cell-cycle pathways re-
sulted in long period length of circadian oscillations, knockdown
of components of folate metabolism resulted in short- and long-
period, as well as high-amplitude, phenotypes. (We note that
components of these pathways often play important roles in
other pathways; for example, several components in insulin
signaling are shared in B cell receptor, IL-4, IL-8, PDGF, and
IGF-1 signaling.) Our previous work has demonstrated that
many components in these pathways are themselves under
clock control and expressed in a circadian fashion in various
peripheral tissues such as the liver (Panda et al., 2002a;Hughes et al., 2009). Collectively, these data show functional
interconnectedness between the circadian clock and many
other biological pathways.
One dramatic example of this regulation is the insulin signaling
pathway (Figure 6A). (Insulin signaling and many other pathways
have inherent feedback mechanisms; in this regard, these path-
ways may not function in a wholly cell-autonomous manner, and
instead may autoregulate in trans.) Downregulation of multiple
components of the insulin pathway resulted in period changes,
including JNK (MAPK8, long period), IKK (IKBKB, long period),
PI3K (PIK3R5, long period), MTOR (FRAP1, long period), APKC
(PRKCI, long period), PFK (PFKP, short period), and PYK
(PKLR, long period) (Figure 6B). In addition, at least 19 compo-
nents of the insulin pathway are regulated at the transcriptional
level by the circadian clock (Figure 6A). These include IKK,
PI3K, and MTOR, whose perturbation also impacts clock func-
tion. To provide additional validation, we employed small mole-
cules targeting multiple components of the insulin pathway in
the U2OS model. SP600125 (a JNK inhibitor) and the Dequali-
nium analog C14 linker (a PKC inhibitor) led to long period length
of circadian oscillations, PMA (a PKC activator) resulted in short
period length, and wortmannin and LY294002 (PI3K inhibitors)
resulted in a phase delay (Figure 6C). These results are all consis-
tent with genetic perturbation of their intended targets. These
results highlight the functional intersection between two impor-
tant biological pathways, insulin signaling and the circadian
clock.
Data Presentation in BioGPS
To facilitate use of this resource, we constructed a database to
enable visualization and exploration. Our screening data are dis-
played as a plug-in in BioGPS, an open-access, searchable
database for aggregating gene annotation from multiple online
sources (http://biogps.gnf.org/). We created a custom BioGPS
circadian layout focused on the siRNA screen described in this
manuscript (Figure S6) and accessible at http://biogps.gnf.org/
circadian/. This BioGPS layout displays plug-ins from our siRNA
circadian screen and a recently published 1 hr resolution circa-
dian gene expression databases from mouse liver and pitui-
tary tissues (Hughes et al., 2009). Additional online resources
are also available including the UCSC Genome Browser
(http://genome.ucsc.edu/), our previously published reference
gene expression data obtained from various tissues and cell
lines (Su et al., 2002; Su et al., 2004), and Wikipedia, which
describes the expanded gene annotations (e.g., PER2 as shown
here). Furthermore, BioGPS provides a flexible platform for
building customized layouts that can be modified to include
a selection of the more than 100 other online data sets and/or
resources in the BioGPS plug-in library.
DISCUSSION
To identify additional clock genes or modulators, we carried out
a genome-wide siRNA screen using a robust reporter gene
assay in human U2OS cells. We found nearly 1000 genes whose
knockdown resulted in low-amplitude circadian oscillations,
whichmay indicate their potential in regulating the general health
of cells. In addition, we found hundreds of genes whoseCell 139, 199–210, October 2, 2009 ª2009 Elsevier Inc. 205
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Figure 4. Dose-Dependent Effects of siRNAs on Clock Gene Expression
(A) Dose-dependent effects on circadian phenotype. Bmal1-dLuc cells were transfected with siRNAs (eight-point, 2-fold dilution series, 8–1000 fmol/well) de-
signed against 11 genes including clock gene controls, and bioluminescence rhythms were recorded. Representative bioluminescence profiles (left) and circa-
dian parameters (right) are indicated. Data represent the mean ± SD (n = 3).
(B and C) Dose-dependent knockdown of target genes (B) and effects on known clock gene expression (C). Bmal1-dLuc cells were transfected with siRNAs
(eight-point, 2-fold dilution series, 24–3000 fmol/well) and analyzed by Q-PCR in unsynchronized conditions. mRNA levels of target gene (left) and ACTB (right,206 Cell 139, 199–210, October 2, 2009 ª2009 Elsevier Inc.
knockdown led to long or short period length of oscillation or
increased amplitude. Many of these factors had phenotypic
effects on the oscillator similar to known clock components
including dose-dependent perturbation. These genes are excel-
lent points of intervention for perturbation of autonomous clock
properties and may later prove important in regulation of physi-
ology and behavior in the whole organism. Molecular analysis
of these dose-dependent genes suggests that most of these
genes function by regulating clock gene expression levels.
These observations point the way to new aspects of genetic
network architecture and possibly new feedback loops in the
clock.
Protein interaction network analysis showed that some factors
physically interact with core clock components, while others
interact with bridging proteins that physically interact with the
clock (one degree of separation). This analysis also showed
that the P53 pathway is functionally interconnected with the
clock. Focused pathway analysis of screen hits dramatically
extend this observation—genes from dozens of pathways are
represented on our hit list, and several pathways, including
insulin and hedgehog signaling, the cell cycle, and folate metab-
as control) relative toGAPDH are indicated in (B), andmRNA levels of nine clock genes relative toGAPDH are indicated in (C). Data represent themean±SD (n = 2).
In parallel experiments, bioluminescence rhythms were recorded and circadian phenotypes were confirmed.
(D) Summary of dose-dependent effects on known clock gene expression.
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Figure 5. The Expanded Clock Gene
Network
Clock components in the core feedback loop
(blue), as well as other clock components known
to regulate clock mechanism (light blue), were
used to identify a list of interactors from the hits
identified in the primary siRNA screen (green, short
period; red, long period; purple, high amplitude)
(Table S2). Protein-protein interactions were col-
lated from Entrez Gene and the Prolexys protein-
protein interaction databases. Common interact-
ing proteins (pink) are depicted as nodes (circles).
Edges are depicted as protein-protein interactions
(black), phosphorylation reactions (blue), transac-
tivation (green), and transrepression (red). The
graph was generated in Cytoscape (http://www.
cytoscape.org/).
olism, are overrepresented. Previous
data has shown that these pathways are
clock regulated. Collectively, we con-
clude the clock is massively intercon-
nected and functionally intertwined with
many biological pathways. As a cau-
tionary note, observations from this cel-
lular model may not be directly applicable
to clock function in thewhole organism as
many genes identified in our screen are
tissue specific.
Why is this interconnectedness im-
portant? Research in other fields has
shown perturbation of one pathway often
has deleterious and unintended conse-
quences on another. For example, COX2 inhibitors such as Vioxx
were designed to inhibit pain and inflammation; however, inter-
mediates produced by COX2 (and inhibited by this class of small
molecules) also afford cardio protection (FitzGerald, 2004). Alter-
natively, this interconnectedness may provide advantages—
many of the above pathways have specific inhibitors that may
prove useful in altering circadian phenotypes. Knowledge of
this interconnectedness will be valuable in exploiting existing
tools while avoiding the potentially deleterious consequences
of doing so blindly.
Finally, we provide a publicly accessible resource to explore
and visualize this data. It is our hope that this resource will serve
as a useful launching point for colleagues studying the circadian
clock in interpretation of their biochemical and genetic results to
accelerate understanding of how the clock regulates physiology
and behavior.
EXPERIMENTAL PROCEDURES
Materials
U2OS cells were obtained from the American Type Culture Collection (ATCC).
We generated Bmal1-dLuc and Per2-dLuc reporter cell lines. The siRNACell 139, 199–210, October 2, 2009 ª2009 Elsevier Inc. 207
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Figure 6. Regulation of Cellular Circadian Clock by Components in the Insulin Signaling Pathway
(A) Insulin signaling pathway genes that impact circadian function. Using the NIH DAVID Pathway Analysis tool, we identified many components of the insulin
signaling pathway represented in our screen hits. Genes that impact clock function and genes regulated by the clock are indicated with colored boxes.
(B) Effects of siRNAs against genes involved in insulin signaling. The representative results from the secondary screen using individual siRNA are presented. Data
represent the mean ± SD (n = 2).
(C) Effects of chemical inhibitors againstprotein kinases involved in insulin signaling.Bioluminescence rhythmsofBmal1-dLuccellsweremonitored in thepresence
of various concentrations of compounds (eight points of 3-fold dilution series; final 3 nM–7 mM). Period or phase parameterwas plotted against final concentrations
of the compound. Data represent the mean ± SD (n = 4). The results for SP600215 and PMA are consistent with our previous observations (Hirota et al., 2008).libraries used in the primary and secondary screens were purchased from
QIAGEN. Additional siRNAs were purchased from Invitrogen and Dharmacon
and used as controls in target validation experiments. GL2 and GL3 siRNAs
designed against the Luc in pGL2 and pGL3 vectors, respectively, were
purchased from QIAGEN. The GL2 siRNA was used as a negative control.
Screen controls purchased from Invitrogen included CRY1-HSS102308,
CRY2-HSS102311, and BMAL1 or ARNTL-HSS100703. CRY1 and NR1D1208 Cell 139, 199–210, October 2, 2009 ª2009 Elsevier Inc.siRNAs used in dose-dependent experiment were previously described
(Baggs et al., 2009). Other siRNAs used in the dose experiment are listed in
Table S3 and were used as pools.
Cell Line Establishment
U2OS cells were grown in regular Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) and antibiotics.
Lentiviral Per2-dLuc and Bmal1-dLuc reporters (Liu et al., 2008) were intro-
duced into U2OS cells via lentivirus-mediated infection as described
(Liu et al., 2008). We selected stable cell lines with blasticidin and clonal lines
by fluorescence-activated cell sorting (FACS)-based single-cell sorting in
96-well plates; we tested these lines as described in the LumiCycle
(Liu et al., 2008). The clonal lines are genetically and morphologically indistin-
guishable from parental cells and represent the average period length of the
infected cell population.
Transfection and ViewLux Recording
For primary siRNA screens, U2OS circadian reporter cells were reverse trans-
fected with siRNAs in 384-well plates. In brief, we trypsinized rapidly growing
cells and resuspended them in DMEM containing 20% FBS without antibiotics
at 0.1 3 106 cells/ml. We next added 20 ml of transfection reagent mixture
(3.3 ml/ml or 0.066 ml/well Lipofectamine 2000 in Opti-MEM) to each well con-
taining prespotted siRNA constructs (1 pmol; 0.5 pmol for each siRNA; final
concentration of 12.5 nM), incubated them at room temperature for 20 min,
and added 20 ml of cells (2000 cells/well) with our robotic system. Approxi-
mately 18 hr after transfection, we replaced this media with 60 ml prewarmed
fresh DMEM containing 10%FBS and antibiotics and allowed the cells to grow
for an additional 2 days.
Three days after transfection, we replaced this media with 60 ml HEPES-
buffered explant medium supplemented with luciferin (1 mM) (Promega) and
B-27 supplements (Invitrogen), and the plates were sealed with an optically
clear film (USA Scientific). We next loaded these plates in a 36C incubator
and recorded bioluminescence expression with a ViewLux (Perkin Elmer).
We measured bioluminescence for 30 s every 2 hr for 4 days. Secondary
screens were performed in the same manner. For technical reasons, 20 out
of the 292 plates in the primary screen were recorded for 3 days.
Data Mining
The primary screen produced a total of >4.33 106 data points (Tables S4 and
S5). We used the MultiCycle circadian data analysis program (Actimetrics) to
analyze recorded bioluminescence data. In brief, data was detrended by
subtraction of a best fit line (first order polynomial) and, subsequently, were
fit to a sine wave to obtain circadian parameters such as rhythm period length
and amplitude.
Mechanistic Validation
The Bmal1-dLuc cells were transfected as described (Hirota et al., 2008) with
a small modification, 0.4 ml/well of Lipofectamine 2000. Parallel transfection
experiments were performed for Q-PCR and functional analyses. For Q-PCR
analysis, the cells were harvested prior to medium change for rhythm
recording and therefore unsynchronized. Total RNA preparation and Q-PCR
were performed as described (Hirota et al., 2008). SYBR Green PCR Master
Mix (Applied Biosystems) or QuantiTect SYBR Green PCR kit (QIAGEN) was
used for Q-PCR. The primers used in Q-PCR analysis are listed in Table S4.
ACCESSION NUMBER
The primary screening data reported in this paper has been deposited in the
PubChem Bioassay database of the National Center for Biotechnology Infor-
mation with the accession number AID 1904.
SUPPLEMENTAL DATA
Supplemental Data include six figures and six tables and can be foundwith this
article online at http://www.cell.com/supplemental/S0092-8674(09)01099-X.
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